These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22939966)

  • 21. The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers.
    Young PM; Wood O; Ooi J; Traini D
    Int J Pharm; 2011 Sep; 416(1):129-35. PubMed ID: 21708238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro characterisation of terbutaline sulphate particles prepared by thermal ink-jet spray freeze drying.
    Sharma G; Mueannoom W; Buanz AB; Taylor KM; Gaisford S
    Int J Pharm; 2013 Apr; 447(1-2):165-70. PubMed ID: 23454848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel dry powder inhalation system based on dispersion of lyophilisates.
    Claus S; Schoenbrodt T; Weiler C; Friess W
    Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses.
    de Boer AH; Hagedoorn P; Westerman EM; Le Brun PP; Heijerman HG; Frijlink HW
    Eur J Pharm Sci; 2006 Jun; 28(3):171-8. PubMed ID: 16650739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated andersen cascade impactors (ACIs): part 2--investigation of bias in extra-fine mass fraction with AIM-HRT impactor.
    Mitchell JP; Nagel MW; Doyle CC; Ali RS; Avvakoumova VI; Christopher JD; Quiroz J; Strickland H; Tougas T; Lyapustina S
    AAPS PharmSciTech; 2010 Sep; 11(3):1115-8. PubMed ID: 20623212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterisation of a carrier-free dry powder aerosol formulation using inertial impaction and laser diffraction.
    Martin GP; MacRitchie HB; Marriott C; Zeng XM
    Pharm Res; 2006 Sep; 23(9):2210-9. PubMed ID: 16900410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Aerodynamic Particle Size Distribution Between a Next Generation Impactor and a Cascade Impactor at a Range of Flow Rates.
    Yoshida H; Kuwana A; Shibata H; Izutsu KI; Goda Y
    AAPS PharmSciTech; 2017 Apr; 18(3):646-653. PubMed ID: 27173989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of sampling volume on dry powder inhaler (DPI)-emitted aerosol aerodynamic particle size distributions (APSDs) measured by the Next-Generation Pharmaceutical Impactor (NGI) and the Andersen eight-stage cascade impactor (ACI).
    Mohammed H; Roberts DL; Copley M; Hammond M; Nichols SC; Mitchell JP
    AAPS PharmSciTech; 2012 Sep; 13(3):875-82. PubMed ID: 22678745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of a cell integrated next-generation impactor to assess in vitro drug transport of physiologically relevant aerosolised particles.
    Wong CYJ; Cuendet M; Spaleniak W; Gholizadeh H; Marasini N; Ong HX; Traini D
    Int J Pharm; 2022 Aug; 624():122024. PubMed ID: 35843365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Comparison of the Performance of Efficient Data Analysis Versus Fine Particle Dose as Metrics for the Quality Control of Aerodynamic Particle Size Distributions of Orally Inhaled Pharmaceuticals.
    Tougas TP; Goodey AP; Hardwell G; Mitchell J; Lyapustina S
    AAPS PharmSciTech; 2017 Feb; 18(2):451-461. PubMed ID: 27068528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aerodynamic sizing of metered dose inhalers: an evaluation of the Andersen and Next Generation pharmaceutical impactors and their USP methods.
    Kamiya A; Sakagami M; Hindle M; Byron PR
    J Pharm Sci; 2004 Jul; 93(7):1828-37. PubMed ID: 15176070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
    Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
    Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Internal Volumes of Pharmaceutical Compendial Induction Port, Next-Generation Impactor With and Without Its Pre-separator, and Several Configurations of the Andersen Cascade Impactor With and Without Pre-separator.
    Roberts DL; Chambers F; Copley M; Mitchell JP
    J Aerosol Med Pulm Drug Deliv; 2020 Aug; 33(4):214-229. PubMed ID: 32101074
    [No Abstract]   [Full Text] [Related]  

  • 35. Addressing the Need for Controls on Particle Bounce and Re-entrainment in the Cascade Impactor and for the Mitigation of Electrostatic Charge for Aerodynamic Particle Size Assessment of Orally Inhaled Products: an Assessment by the International Consortium on Regulation and Science (IPAC-RS).
    Doub W; Stein S; Mitchell J; Goodey AP
    AAPS PharmSciTech; 2020 Aug; 21(7):239. PubMed ID: 32827121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro evaluation of the DP-4M PennCentury insufflator.
    Hoppentocht M; Hoste C; Hagedoorn P; Frijlink HW; de Boer AH
    Eur J Pharm Biopharm; 2014 Sep; 88(1):153-9. PubMed ID: 24993307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aerosol characterisation of nebulised liposomes co-loaded with erlotinib and genistein using an abbreviated cascade impactor method.
    Nimmano N; Somavarapu S; Taylor KMG
    Int J Pharm; 2018 May; 542(1-2):8-17. PubMed ID: 29496458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of dry powder inhaler (DPI) resistance and aerosol dispersion timing on emitted aerosol aerodynamic particle sizing by multistage cascade impactor when sampled volume is reduced from compendial value of 4 L.
    Mohammed H; Arp J; Chambers F; Copley M; Glaab V; Hammond M; Solomon D; Bradford K; Russell T; Sizer Y; Nichols SC; Roberts DL; Shelton C; Greguletz R; Mitchell JP
    AAPS PharmSciTech; 2014 Oct; 15(5):1126-37. PubMed ID: 24871551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aerosol tribocharging and its relation to the deposition of Oxis™ Turbuhaler® in the electrical next generation impactor.
    Hoe S; Young PM; Traini D
    J Pharm Sci; 2011 Dec; 100(12):5270-80. PubMed ID: 21850666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aiming for a moving target: challenges with impactor measurements of MDI aerosols.
    Stein SW
    Int J Pharm; 2008 May; 355(1-2):53-61. PubMed ID: 18191510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.